Eugene Pashkovetsky, MD
Cardiovascular Disease · Albany, NYNPI 1588930770
Payments from drug & device makers
Across 668 payments — averaging $77.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$38K
- Abbott$2K
- AstraZeneca$2K
- Novartis$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$905
- Pfizer$818
- plus $6K from 27 others
What the payments were for
- Consulting fees$5,38521%
- Speaking & faculty fees$6,54725%
- Travel & lodging$1,8727%
- Food & beverage$12,05847%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 79 | $38,482 |
| Abbott | 30 | $2,208 |
| AstraZeneca | 44 | $1,933 |
| Novartis | 183 | $1,712 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $905 |
| Pfizer | 52 | $818 |
| Boehringer Ingelheim | 31 | $810 |
| Alnylam Pharmaceuticals Inc. | 25 | $654 |
| Merck | 34 | $602 |
| Johnson & Johnson | 27 | $599 |
| Amgen | 20 | $345 |
| Bayer | 11 | $339 |
| Abiomed | 9 | $330 |
| AOP Health US, LLC | 1 | $326 |
| Actelion Pharmaceuticals US, Inc. | 10 | $308 |
| Cvrx, Inc. | 28 | $215 |
| Lexicon Pharmaceuticals, Inc. | 11 | $185 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $172 |
| Kiniksa Pharmaceuticals, Ltd. | 12 | $170 |
| Scpharmaceuticals Inc. | 6 | $105 |
| Bridgebio Pharma, Inc. | 5 | $102 |
| Esperion Therapeutics, Inc. | 5 | $82 |
| Boston Scientific | 3 | $72 |
| Impulse Dynamics (USA) Inc. | 2 | $63 |
| Chiesi USA, Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Novo Nordisk | 2 | $43 |
| GSK | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Amarin Pharma, Inc. | 1 | $35 |
| Portola Pharmaceuticals, LLC | 2 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$7,105
- HeartMate PHP$1,207
- FARXIGA$930
- Rapiblyk$653
- HeartMate 3 Left Ventricular Assist Device$134
- CardioMEMS HF System$129
- AMVUTTRA$123
- Adempas$123
- JARDIANCE$123
- UPTRAVI$122
- OPSUMIT$122
- Impella$116
- XARELTO$108
How this compares
$51,854 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 90 | $2,730,800 |
| CamzyosMavacamten | 71 | $579,236 |
| EliquisApixaban | 348 | $475,641 |
| VyndaqelTafamidis Meglumine | 14 | $389,398 |
| EntrestoSacubitril/Valsartan | 119 | $180,973 |
| JardianceEmpagliflozin | 123 | $162,277 |
| FarxigaDapagliflozin Propanediol | 103 | $153,903 |
| Repatha SureclickEvolocumab | 39 | $48,432 |
| XareltoRivaroxaban | 39 | $46,720 |
| OzempicSemaglutide | 22 | $37,525 |
| VerquvoVericiguat | 24 | $27,984 |
| WegovySemaglutide | 19 | $24,351 |
| Praluent PenAlirocumab | 27 | $18,483 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $11,948 |
| Bumetanide | 215 | $8,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis, Vyndaqel | $818 | $3,595,838452 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $38,482 | $579,23671 claims |
| NovartisEntresto | $1,712 | $180,973119 claims |
| Boehringer IngelheimJardiance | $810 | $162,277123 claims |
| AstraZenecaFarxiga | $1,933 | $153,903103 claims |
| Novo NordiskOzempic, Wegovy | $43 | $61,87541 claims |
| Johnson & JohnsonXarelto | $599 | $46,72039 claims |
| MerckVerquvo | $602 | $27,98424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Albany
- Augustin DelagoAlbany$2M
- Rizwan AlimohammadAlbany$624K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.